Krystal Biotech (KRYS) News
NASDAQ: KRYSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
308.89-6.93 (-2.19%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
KRYS news summary
We found 48 recent headlines mentioning Krystal Biotech (KRYS): 0 in the past week and 15 in the past 30 days, most often from Seeking Alpha, Nasdaq, GlobeNewswire. For price context, KRYS is down 2.19% at $308.89. The most recent story, "Krystal Biotech to Present at Upcoming Investor Conferences", was published by GlobeNewswire on Nov 10, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Krystal Biotech headlines
- Krystal Biotech to Present at Upcoming Investor ConferencesPITTSBURGH, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that management will take part in fireside chats and host investor meetings at the…GlobeNewswire
- Krystal Biotech, Inc. 2026 Q3 - Results - Earnings Call PresentationSeeking Alpha
- Krystal's Q3 Profit Declines As Clinical Portfolio Advances; Stock Dips By Over 12%(RTTNews) - Krystal Biotech Inc. (KRYS), a commercial-stage biotechnology company, on Monday released financial results for the third quarter, recording a lower profit as high revenues were offset by…Nasdaq
- Krystal Biotech, Inc. (KRYS) Q3 2026 Earnings Call TranscriptSeeking Alpha
- Krystal Biotech (KRYS) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- Krystal Biotech Q3 Earnings Call Highlights3 Biotech Firms With Major Potential Catalysts in the Coming MonthsKrystal Biotech (NASDAQ:KRYS) reported third-quarter 2026 revenue growth driven by continued adoption of its VYJUVEK treatment in…Nasdaq
- Krystal Biotech falls as data for pipeline programs pushed to 2027Seeking Alpha
- Krystal Biotech, Inc. (KRYS) Surpasses Q3 Earnings and Revenue EstimatesKrystal Biotech (KRYS) delivered earnings and revenue surprises of +11.41% and +2.16%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?NasdaqKRYS, ARMP
- Krystal Biotech GAAP EPS of $2.05 beats by $0.28, revenue of $1.1B beats by $973.46MSeeking Alpha
- Krystal Biotech, Inc. Q3 Profit Retreats(RTTNews) - Krystal Biotech, Inc. (KRYS) released earnings for third quarter that Dropped, from the same period last yearNasdaq
- Krystal Biotech Announces Third Quarter 2026 Financial and Operating Results<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p align="center" style="text-align:center;">$127.3 million in 3Q VYJUVEK global revenue and $1.1…Business Insider
- Krystal Biotech Announces Third Quarter 2026 Financial and Operating Results$127.3 million in 3Q VYJUVEK global revenue and $1.1 billion since launchGlobeNewswire
- Krystal Biotech Q3 Earnings PreviewSeeking Alpha
- Amgen (AMGN) Reports Next Week: Wall Street Expects Earnings GrowthAmgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.NasdaqAMGN, KRYS
- Analysts Estimate Krystal Biotech, Inc. (KRYS) to Report a Decline in Earnings: What to Look Out forKrystal Biotech (KRYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.NasdaqKRYS, ALNY
- Krystal Biotech to Report Third Quarter 2026 Financial Results on November 2, 2026PITTSBURGH, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its third quarter 2026 financial results on Monday, November 2,…GlobeNewswire
- Weekly Buzz: RHHBY, TEVA Win FDA Nod; MLAB, GSK Cut Jobs; AZN, VIR Deals; KRYS, ABBV Report Data(RTTNews) - This week's healthcare roundup brings a series of regulatory wins, corporate restructuring, billion-dollar deals and clinical milestones.NasdaqABBV, ANL, ARWR, AZN
- KRYS Reports Positive Early Data for KB113 in Gorlin SyndromeKrystal Biotech reports promising early results for KB113, with tumor regression seen in more than 80% of assessed lesions in an early Gorlin syndrome study.NasdaqKRYS, HALO, ARVN, HOWL
- Krystal Biotech Sees Broad Antitumor Activity With KB113 In Gorlin Syndrome; Stock Up(RTTNews) - Krystal Biotech, Inc. (KRYS) announced positive preliminary clinical data for KB113, an investigational immunotherapy designed to treat basal cell carcinomas (BCCs) in patients with…NasdaqKRYS, BRK.A
- Krystal Biotech Reports Over 80% Lesion Regression With KB113 In Gorlin Syndrome(RTTNews) - Thursday, Krystal Biotech, Inc. (KRYS) announced positive preliminary clinical data for KB113, an investigational intratumoral immunotherapy being developed to treat basal cell carcinomas…Nasdaq
- FDA unveils rare disease initiative to enhance therapy developmentSeeking Alpha
- Krystal Biotech: Vyjuvek's Success Is Becoming Its Growth Problem (Downgrade)Seeking Alpha
- Krystal Biotech: My Analysis Suggests Stock Has Not Yet Reached Peak ValueSeeking Alpha
- Notable ETF Outflow Detected - IWO, FROG, BTSG, KRYSLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 2000 Growth ETF (Symbol: IWO) where we have detected…NasdaqIWO, FROG, BTSG, KRYS
- Krystal Stock Gains 13.4% in a Month: What Is Driving the Rally?KRYS' Vyjuvek growth and expanding genetic medicine pipeline boost investor confidence as the company advances toward multi-product growth.NasdaqKRYS, ALDX, ACIU, PGEN
- Why Is Amgen (AMGN) Up 8.6% Since Last Earnings Report?Amgen (AMGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.NasdaqAMGN, KRYS
- Krystal Biotech (KRYS) Up 12% Since Last Earnings Report: Can It Continue?Krystal Biotech (KRYS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.NasdaqKRYS, AZN
- Noteworthy Friday Option Activity: PZZA, CRK, KRYSAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Papa John's International, Inc. (Symbol: PZZA), where a total of 25,286 contracts have…NasdaqPZZA, CRK, KRYS
- Vertex Pharmaceuticals Just Hit an All-Time High. Here's Why the Biotech Stock Could Soar Even MoreKey PointsVertex Pharmaceuticals appears likely to continue to dominate its core therapeutic area.NasdaqVRTX, ABBV, KRYS, SION
- Krystal Biotech (KRYS) Q2 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- Krystal Biotech, Inc. 2026 Q2 - Results - Earnings Call PresentationSeeking Alpha
- iShares Russell 2000 Growth ETF Experiences Big OutflowLooking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Russell 2000 Growth ETF (Symbol: IWO) where we have detected…NasdaqIWO, FROG, GKOS, KRYS
- Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in FocusKRYS tops Q2 EPS estimates as Vyjuvek sales climb 24%, but its shares fall despite broader access, global expansion and pipeline progress.NasdaqKRYS, NBIX, LQDA, HRMY
- Krystal Biotech, Inc. (KRYS) Q2 2026 Earnings Call TranscriptSeeking Alpha
- Pre-Market Earnings Report for August 3, 2026 : MAR, TSN, CNA, ECHO, CNH, KRYS, TGTX, TWST, HESM, MMYT, AVA, SRADThe following companies are expected to report earnings prior to market open on 08/03/2026. Visit our Earnings Calendar for a full list of expected earnings releases.Marriott International (MAR)is…NasdaqMAR, TSN, CNA, ECHO
- Krystal Biotech: International Expansion And A Vibrant PipelineSeeking Alpha
- Krystal Biotech: Profitable, Self-Funding, And Loaded With OptionalitySeeking Alpha
- Krystal Biotech, Inc. (KRYS) Presents at Bank of America Global Healthcare Conference 2026 TranscriptSeeking AlphaKRYS, BAC
- Krystal Biotech: Vyjuvek Is Not The Primary AssetSeeking Alpha
- Krystal Biotech, Inc. 2026 Q1 - Results - Earnings Call PresentationSeeking Alpha
- Krystal Biotech: A Q1 Earnings Beat With Multiple Catalysts In 2026 And 2027Seeking Alpha
- Krystal Biotech, Inc. (KRYS) Q1 2026 Earnings Call TranscriptSeeking Alpha
- Krystal Biotech, Inc. (KRYS) Q4 2025 Earnings Call TranscriptSeeking Alpha
- Krystal: Profitable Growth And The Expanding Reach Of HSV-1 TechnologySeeking Alpha
- Krystal Biotech, Inc. 2025 Q4 - Results - Earnings Call PresentationSeeking Alpha
- Krystal Biotech: KB707 Program Bolstered By RMAT And 2nd Half 2026 UpdateSeeking Alpha
- Krystal Biotech: Beyond VYJUVEK CommercializationSeeking Alpha
- Krystal Biotech, Inc. (KRYS) Presents at 44th Annual J.P. Morgan Healthcare Conference - SlideshowSeeking Alpha